1. Anti-Cancer Effects of Pristimerin and the Mechanisms: A Critical Review
   Jia-jun Li et al, 2019, Front. Pharmacol. CrossRef
2. bta-miR-23a Regulates the Myogenic Differentiation of Fetal Bovine Skeletal Muscle-Derived Progenitor Cells by Targeting MDFIC Gene
   Xin Hu et al, 2020, Genes CrossRef
3. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer
   Bartosz Mateusz Gąsiorkiewicz et al, 2020, Invest New Drugs CrossRef
4. Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances
   Run-Ze Chen et al, 2021, Front. Oncol. CrossRef
5. Impact of Non-Coding RNAs on Chemotherapeutic Resistance in Oral Cancer
   Karen Yamaguchi et al, 2022, Biomolecules CrossRef
6. A Link Between Chemical Structure and Biological Activity in Triterpenoids
   Li Zang et al, 2022, PRA CrossRef
7. Pristimerin in Oxidative Stress and Use in Cancer
   Ana Carolina B. da C. Rodrigues et al, 2021 CrossRef
8. MicroRNAs as Predictors of Lung-Cancer Resistance and Sensitivity to Cisplatin
   Maria Konoshenko et al, 2022, IJMS CrossRef
9. Berbamine Hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells
   Yujuan Zhan et al, 2022, Cell Biol Toxicol CrossRef
10. Pristimerin in Oxidative Stress and Use in Cancer
    Ana Carolina B. da C. Rodrigues et al, 2022 CrossRef
11. Focusing on the Role of Natural Products in Overcoming Cancer Drug Resistance: An Autophagy-Based Perspective
    Jiaqi Yao et al, 2022, Biomolecules CrossRef
12. Accurate delivery of pristimerin and paclitaxel by folic acid-linked nano-micelles for enhancing chemosensitivity in cancer therapy
    Chao Chen et al, 2022, Nano Convergence CrossRef
13. Neuroplasticity to autophagy cross-talk in a therapeutic effect of physical exercises and irisin in ADHD
    Alhasan Abdulghani et al, 2023, Front. Mol. Neurosci. CrossRef
14. The mechanism and application of traditional Chinese medicine extracts in the treatment of lung cancer and other lung-related diseases
    Zhenglin He et al, 2023, Front. Pharmacol. CrossRef
15. Pristimerin suppresses AIM2 inflammasome by modulating AIM2-PYCARD/ASC stability via selective autophagy to alleviate tendinopathy
    Huaji Jiang et al, 2024, Autophagy CrossRef
16. ATTEMPTS TO SYNTHESIZE A TRIMERIC DERIVATIVE OF PRISTIMERIN WITH POTENTIAL ACTIVITY AGAINST CANCER CELLS
    Josana Pereira Dos Santos et al, 2024, Rev. Contemp. CrossRef
17. Pristimerin Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review
    Jian Sun et al, 2024, DDDT CrossRef